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and its Application in MHC Exchange Reagents for T Cell
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Ton N. M. Schumacher,[b] Boris Rodenko,*[a] and Huib Ovaa*[a]
Introduction
Cleavable linkers are key tools in many fields of biology, rang-
ing from proteomics and protein purification to structural biol-
ogy. The development of linkers that can be cleaved under
biocompatible reaction conditions is a challenge for chemists.
A high cleavage rate, efficiency and selectivity are desired, but
protein structure and function must not be compromised. This
demands mild cleavage conditions in an environment that is
dictated by the application (physiological or biochemical, in
vivo or in vitro, reducing or pH-neutral, for example). A cleava-
ble linker that can replace an amino acid residue in the back-
bone of a (poly)peptide or protein will allow cleavage of the
backbone into at least two fragments upon application of a de-
fined trigger, but will require accessibility of the cleavage site
to the trigger. To date, various cleavable moieties that can be
cleaved by photoirradiation, enzymes, nucleophilic or electro-
philic reagents and reducing or oxidizing reagents have been
developed for incorporation into the backbones of peptides or
proteins.[1] Although photocleavable linkers are widely used,
UV irradiation has several drawbacks, such as 1) the uncontrol-
led increase in temperature and concomitant evaporation of
medium or buffer that can be caused by the heat generated
by a UV lamp, 2) incomplete cleavage due to limited penetra-
tion of UV light into the sample medium, and 3) uneven UV ex-
posure of wells in microtiter plates in high-throughput screen-
ing applications, leading to distorted assay results. A chemical
trigger circumvents these problems, is readily available, can be
added and quenched in a controlled fashion and under sterile
conditions and does not require special laboratory equipment
such as a UV lamp. Linkers that can be cleaved under mild oxi-
dative conditions have an advantage over linkers sensitive to
reductive conditions: they allow preservation of disulfide
bonds and hence protein structure.
The vicinal diol moiety has been used as an oxidation-sensi-
tive linker[1] and is cleaved by the mild oxidant sodium period-
ate to yield two aldehyde fragments. Periodate-mediated diol
cleavage is a mild and biocompatible reaction, but it has one
major drawback: complete cleavage of a diol linkage requires
periodate concentrations in the millimolar range and incuba-
tion times of the order of hours. This invariably leads to co-oxi-
dation of cysteine and methionine residues.[2] Such co-oxida-
tions can affect protein function and protein–ligand and/or
protein–protein interactions.[3]
We decided to develop a biocompatible, cleavable linker
that would be amenable to incorporation into a (poly)peptide
Incorporation of cleavable linkers into peptides and proteins is
of particular value in the study of biological processes. Here
we describe the synthesis of a cleavable linker that is hyper-
sensitive to oxidative cleavage as the result of the periodate
reactivity of a vicinal amino alcohol moiety. Two strategies di-
rected towards the synthesis of a building block suitable for
solid-phase peptide synthesis were developed: a chemoenzy-
matic route, involving l-threonine aldolase, and an enantio-
selective chemical route; these led to a,g-diamino-b-hydroxy-
butanoic acids in diastereoisomerically mixed and enantiopure
forms, respectively. Incorporation of the 1,2-amino alcohol link-
er into the backbone of a peptide generated a conditional
peptide that was rapidly cleaved at very low concentrations of
sodium periodate. This cleavable peptide ligand was applied in
the generation of MHC exchange reagents for the detection of
antigen-specific T cells in peripheral blood cells. The extremely
low concentration of periodate required to trigger MHC pep-
tide exchange allowed the co-oxidation of methionine and
disulfide residues to be avoided. Conditional MHC reagents
hypersensitive to periodate can now be applied without limita-
tions when UV irradiation is undesired or less practical.
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backbone and would also be hypersensitive to periodate oxi-
dation, allowing selective cleavage, but without unwanted co-
oxidation reactions. The periodate-mediated cleavage rate of
a vicinal amino alcohol is reportedly 1000 times higher than
that of a vicinal diol,[4] so we aimed at the generation of
a linker system containing a 1,2-amino alcohol fragment as
shown in Scheme 1. Here we present the synthesis and strin-
gent evaluation of this linker in a biological system in which
the prevention of methionine oxidation is of critical impor-
tance: the major histocompatibility complex (MHC) class I–anti-
genic peptide–T-cell receptor interaction. Major histocompati-
bility class I complexes present peptide antigens at the cell sur-
face for surveillance by cytotoxic T cells, forming the basis for
a subsequent antigen-specific cytotoxic T cell response. T-cell
receptors recognise the composite surface of the antigenic
peptide-MHC class I complex (pMHC). Small changes in this
surface, such as oxidation of a methionine residue in the anti-
genic peptide, result in distorted interaction with the T-cell re-
ceptor, and this has led to impaired T cell staining with use of
MHC tetramers[5] generated by MHC exchange reactions.[6] We
show that the vicinal amino alcohol linker developed here cir-
cumvents these co-oxidation issues in MHC exchange technol-
ogy, which has become a standard tool for immunologists
monitoring T cell specificities in a high-throughput fashion.
Results
Chemoenzymatic synthesis of 1,2-amino-alcohol-containing
b-amino acids
Although various synthetic routes for the preparation of vicinal
amino alcohols—such as oxyamination[7] or dihydroxylation[8]
of olefins, ring opening of aziridine[9] and enzymatic process-
es[10]—have been developed, none of them allows incorpora-
tion of a vicinal amino alcohol group in the main carbon chain,
so they are unsuited as synthetic approaches to the prepara-
tion of a backbone-cleavable amino acid residue. To generate
the amino acid residue a,g-diamino-b-hydroxybutanoic acid
(DAHB), suitable for solid-phase peptide synthesis (SPPS), we
used two different approaches: a biocatalytic route that gives
the desired vicinal amino alcohol moiety in only few steps as
a mixture of diastereoisomers [(2S,3R)- and (2S,3S)-DAHB] and,
alternatively, a chemical route that requires more synthetic
steps, but allows easy scale-up and furnishes only one diaste-
reoisomer [(2S,3R)-DAHB]. Furthermore, to allow for easy incor-
poration in the backbone of a peptide ligand by automated
solid-phase synthesis, we included orthogonal protective
groups in the design of functionalised DAHB building blocks.
The chemoenzymatic approach involved the application of an
aldol reaction catalysed by recombinant l-threonine aldolase
(LTA) from Pseudomonas putida (Scheme 2). This aldolase catal-
yses aldol condensations between glycine and appropriate al-
dehydes, with formation of CC bonds with high stereoselec-
tivity at the a-carbons to give the l-epimers. Although LTA
from Pseudomonas putida is known to render modest enantio-
selectivity at the b-carbon chiral centres, we selected this
enzyme for its tolerance of a broad range of aldehydes.[10a,11]
LTA from P. putida was cloned and expressed in E. coli, and
lysate containing LTA was used without further purification
(Figure S1 in the Supporting Information). We studied the effi-
ciency of the biocatalysed reaction with 2-aminoacetaldehyde
bearing Fmoc (compound 1a) or Alloc (compound 1b) as N-
protecting groups; these compounds were easily prepared by
literature procedures.[12] Enzymatic aldol condensations were
performed at room temperature in aqueous phosphate buffer,
with 2.7 equivalents of glycine and catalytic amounts of pyri-
doxal-5’-phosphate as the cofactor. The reactions were moni-
tored by TLC and LC-MS and quenched by addition of CH3OH/
AcOH (9:1, v/v) to avoid retroaldol reactions. Solubilisation of
starting material 1a required addition of DMSO (12%) to the
reaction mixture. After purification over a solid-phase extrac-
tion column, amino alcohol 2a was obtained in 10% yield. The
presence of the organic solvent seemed to affect the efficiency
of the enzymatic reaction: when N-Alloc-protected 1b was
used as the aldehyde component, DMSO was not required for
its solubilisation and the reaction proceeded smoothly in phos-
phate buffer to give 2b in good yield (50%) after flash chro-
matography.
Next, the Na atoms in 2a and 2b were protected with acid-
labile Boc groups for subsequent use in Fmoc-based SPPS;
Scheme 1. An a,g-diamino-b-hydroxybutanoic acid (DAHB) residue incorpo-
rated into a peptide backbone is cleaved by NaIO4 much more rapidly than
a g-amino-a,b-dihydroxybutanoic acid residue.
Scheme 2. Chemoenzymatic synthesis of l-DAHB building blocks for SPPS.
a) LTA lysate, glycine (2.7 equiv), pyridoxal-5’-phosphate (0.025 equiv), RT, 3–
16 h, 10% for 2a and 50% for 2b ; b) (Boc)2O (1.1 equiv), NaHCO3 (2 equiv),
H2O/dioxane, 53% for 3a and 40% for 3b.
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l-DAHB derivatives 3a and 3b were obtained in 53 and 40%
yields, respectively. Maintaining the pH between 8 and 9
during the Boc protection step was essential to avoid retroal-
dol reactions, which are favoured at pH>9. The peaks of the
syn and anti isomers of 3a were discernible by HPLC and the
syn/anti ratio was 40:60 (Figure S2), a typical diastereomeric
ratio for aldol reactions catalysed by P. putida LTA.[13] For prod-
ucts 2a, 2b and 3b the syn and anti isomers were not re-
solved by HPLC, and their diastereomeric ratios could not be
determined. Protection of the b-hydroxy groups was not nec-
essary, because O-acylation does not occur with use of PyBop
as the coupling reagent in standard Fmoc-based SPPS.
Enantioselective synthesis of a b-amino acid containing a
1,2-amino alcohol system
The diastereoisomers of building blocks 3 obtained by the che-
moenzymatic route were difficult to separate. In order to study
the requirement for diastereoselectivity with regard to the pe-
riodate susceptibility of an amino alcohol moiety conforma-
tionally restrained in a peptide, we developed an alternative,
enantioselective route to building blocks containing vicinal
amino alcohol systems; this additionally gave access to differ-
ent and orthogonal protective groups and allowed for easy
scale-up (Scheme 3). Isopropylidene-protected vicinal diol 4[3b]
was treated with TFA in a THF/H2O mixture to furnish diol 5,
which, after solvent evaporation, was immediately taken up in
methanol containing a catalytic amount of HCl to furnish the
corresponding methyl ester 6 in 77% yield. Treatment of diol 6
with thionyl chloride and triethylamine at 0 8C then gave sulfite
7 in 80% yield. Direct ring opening of the sulfite was unsuc-
cessful, so compound 7 was oxidized with NaIO4 and a catalytic
amount of RuCl3·xH2O to afford sulfate 8 in 80% yield. Nucleo-
philic ring opening of 8 with sodium azide was performed in
an acetone/water mixture at room temperature to provide
azido alcohol 9 in 64% yield after column chromatography.
Finally, mild hydrolysis with trimethyltin hydroxide[14] furnished
the desired masked amino alcohol building block 10—in
which the a-amino group was masked as an azide, to be re-
duced after incorporation into the peptide—in 68% yield and
as the single l-syn isomer.
With building blocks syn/anti-3a/3b and syn-10 in hand we
set out to synthesise a chemocleavable peptide containing an
amino alcohol system as a conditional ligand for MHC ex-
change applications. Reagent accessibility is a key determinant
in the efficiency of periodate cleavage and subsequent antigen
exchange.[3b] The crystal structures of human leukocyte anti-
gen-A2.1 (HLA-A2.1) loaded with various viral epitopes,[15] in-
cluding native cytomegalovirus (CMV) pp65(495–503) peptide,
[16]
or NLVJMVATV in which J is a diol residue,[3b] show that the
p4 position is the most solvent-accessible position. We there-
fore incorporated the masked amino acid residues 3a, 3b and
10 at the p4 position in the HLA-A2.1 restricted CMV pp65(495–
503) epitope, resulting in NLVBMVATV, in which B designates the
amino alcohol residue. By automated Fmoc-based SPPS we
generated conditional peptide p*AA both as a syn/anti mixture
of diastereomers (termed p*AAsyn/anti) by utilizing syn/anti-3a/
3b and as a single diastereoisomer (termed p*AAsyn) from syn-
10.
Chemosensitivity and MHC exchange reactions
The sensitivity of p*AA towards sodium periodate was studied
and compared with that of the diol-containing peptide ana-
logue (termed p*DI). The oxidation-sensitive peptides were
subjected to various amounts of NaIO4 and the resulting mix-
tures were analysed by LC-MS (Figures S3 and S4). Complete
cleavage of the hypersensitive p*AA was achieved within
10 min with use of only two equivalents of periodate; as ex-
pected, this was much faster and milder than the conditions
required for cleavage of p*DI, which required at least 30 equiv-
alents of NaIO4 and 2 h incubation time. Peptide p*AA con-
tains a methionine residue, and we observed that partial me-
thionine oxidation only occurred when p*AA was treated with
>3 equiv of NaIO4; this indicates that methionine oxidation
was slower than amino alcohol cleavage.
We next loaded p*AAsyn or p*AAsyn/anti into the MHC class I
peptide binding groove of HLA-A2.1 by a standard refolding
procedure.[20] Chemocleavage of the conditional peptide
lodged in the peptide binding groove should demand accessi-
bility of the amino alcohol moiety to periodate anions, as well
as an orientation of the vicinal amino alcohol that sterically
allows the formation of the cyclic periodate ester intermedi-
ate.[17] In view of the constrained conformation of the peptide
ligand in the MHC groove, we investigated (by HPLC analysis)
whether the loaded ligands p*AAsyn or p*AAsyn/anti would show
differential reactivities towards periodate. Treatment of HLA-
A2.1::p*AAsyn/anti or HLA-A2.1::p*AAsyn with as little as 10 mm
NaIO4 in the presence of a nonbinding HLA-B7 restricted
Scheme 3. Enantioselective synthesis of a masked DAHB building block for
SPPS. Reagents and conditions: a) TFA, THF/H2O, 4 h; b) CH3OH, HCl (cat),
65 8C, 6 h, 77% over two steps; c) SOCl2 (2.2 equiv), Et3N (4.4 equiv), CH2Cl2,
0 8C, 1.5 h, 80%; d) RuCl3·xH2O (0.01 equiv), NaIO4 (2 equiv), CCl4/CH3CN/H2O
(1:1:1.2), RT, 1 h, 80%; e) NaN3 (2 equiv), acetone/H2O, 0 8C!RT, 16 h, 64%;
f) Me3SnOH, DCE, 82 8C, 3 h, 68%.
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mage-1 epitope resulted in degradation of the conditional
MHC complex (p*MHC) as a result of efficient oxidative cleav-
age (Figure 1A and B). A peptide exchange experiment with
HLA-A2 restricted CMV epitope, triggered by 10 mm NaIO4, re-
sulted in rescue of the MHC complex (Figure 1C and D). No
difference in reactivity between MHC loaded with p*AAsyn or
with p*AAsyn/anti was observed, which implied that the confor-
mational restrictions in the MHC peptide binding groove have
no appreciable influence on cleavage of the conditional pep-
tide.
MHC exchange reactions and T cell characterisation
We used refolded and biotinylated HLA-A2.1::p*AAsyn/anti for
MHC exchange reactions and converted these MHC reagents
into tetramers by addition of phycoerythrin-conjugated (PE-
conjugated) streptavidin. We studied the performance of these
hyper-chemosensitive MHC exchange reagents in the detec-
tion of antigen-specific T cells in peripheral blood samples by
flow cytometry.
All exchange reactions mentioned from this point onwards
were additionally performed with refolded and biotinylated
HLA-A2.1::p*AAsyn ; the T cell staining results were similar to
those obtained with biotinylated HLA-A2.1::p*AAsyn/anti (Sup-
porting Information). This confirms that diastereomeric purity
of the amino alcohol component is not a requirement for effi-
cient MHC peptide exchange reactions.
Peptide exchange reactions with HLA-A2.1::p*AA were trig-
gered by the addition of only 10 mm NaIO4, a concentration 30
times lower than that required with diol-based HLA-A2.1::p*DI.
We observed that periodate-exchanged MHC tetramers con-
taining influenza epitope GILGFVFTL stain low-frequency influ-
enza epitope-specific T cells in peripheral blood mononuclear
cells (PBMCs) from a healthy individual as efficiently as photo-
exchanged MHC class I tetramers (Figure 2A and Figure S8).
Importantly, hypersensitive periodate-exchanged tetramers
containing CMV epitope NLVPMVATV stain low-magnitude
PBMCs from an HLA-A2.1-positive individual very efficiently,
which implies that methionine oxidation, which would hamper
interaction with the T-cell receptor, does not occur under
these mild conditions. In contrast, treatment with 300 mm of
NaIO4—the conditions needed for chemo-exchange of the
diol-based p*MHC—impeded Tcell staining, due to concomi-
tant oxidation of the methionine residue (Figure 2B). Staining
of PBMCs with MHC tetramers obtained by hypersensitive
chemo-exchange was not donor-dependent (Figure S9).
MHC tetramers generated by the hypersensitive chemo-
exchange reaction of HLA-A2.1::p*AA with Epstein–Barr virus
(EBV) epitope GLCTLVAML, containing both an oxidation-sensi-
tive Cys residue and an oxidation-sensitive Met residue, did
not stain PBMCs from an HLA-A2.1/EBV-positive individual (Fig-
ure S10). We attributed the impaired performance of these
chemo-exchange tetramers to the presence of the cysteine res-
idue. Isosteric replacement, a work-around that we have used
before, gave variable, donor-dependent results in T cell stain-
ing by chemo-exchanged tetramers.[3b] We therefore turned to
another strategy: cysteine caging, which has been made feasi-
ble by the extremely mild oxidative cleavage conditions used
here, which preclude disulfide oxidation.[18] This concept is
based on protecting the cysteine residue in the epitope in the
form of a disulfide that is liberated, after hypersensitive
chemo-exchange, by a mild reducing reagent such as dithio-
threitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP), thereby
regenerating a free cysteine residue without compromising
MHC integrity (Figure 3A). The cysteine residue of the EBV epi-
tope was caged as a thiopropanoic acid disulfide, termed EBV-
SPa (Figure S5). Exchange tetramers containing EBV-SPa did
not stain peripheral blood cells of an EBV-positive donor, but
treatment of EBV-Spa-exchanged monomers with either DTT or
TCEP followed by tetramerisation resulted in efficient detection
of EBV-positive cytotoxic T lymphocytes (Figure 3B and Fig-
ure S11).
We also investigated the use of thiomethyl and thio-tert-
butyl disulfides as caging groups, but these gave suboptimal
results (Figures S6, S7, S12 and S13). To show the functionality
of T cells interacting with chemo-exchanged multimers we per-
formed a cytokine (IFN-g) release assay, which revealed that
chemo-exchanged multimers containing an uncaged EBV-Spa
epitope activate an EBV-positive T-cell clone as efficiently as
UV-exchanged multimers (Figure 3C).
Figure 1. Peptide exchange efficiency as monitored by gel filtration HPLC
analysis and UV absorbance (230 nm). A) HLA-A2.1::p*AAsyn/anti (0.5 mm)
before (solid line) or after treatment with either 10 mm (dashed line) or
30 mm (dotted line) NaIO4 in the presence of 50 mm of nonbinding peptide
(HLA-B7 restricted mage-1(289–298) epitope RVRFFFPSL). B) As in A), but with
0.5 mm HLA-A2.1::p*AAsyn. C) Chemo-exchange of 0.5 mm HLA-A2.1::p*AAsyn/anti
before (solid line) or after treatment with 10 mm NaIO4 (dashed line) in the
presence of 50 mm of rescue peptide (HLA-A2 restricted CMV pp65(495–503)
epitope NLVPMVATV). D) As in C), but with 0.5 mm HLA-A2.1::p*AAsyn.
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Discussion
We have developed synthetic routes—one giving a diastereo-
meric mixture and one enantiopure—to vicinal amino alcohol
building blocks for application in SPPS. If diastereomeric purity
is not essential, as was the case for periodate-triggered MHC
peptide exchange, we recommend the use of the racemic syn/
anti-l-DAHB building blocks 3a (N-Fmoc-protected) or 3b (N-
Alloc-protected), given their ease of synthesis (only two steps
from the protected 2-aminoacetaldehydes). The higher yields
obtained in the synthesis of N-Alloc-protected 3b would
favour the use of this building block. However, if such yields
are of no concern, the direct applicability of N-Fmoc-protected
3a in standard Fmoc-based SPPS protocols is a clear advant-
age.
Since its introduction in 2006,[6a] MHC exchange technology
has become a standard tool for immunologists studying T cell
selectivity and reactivity, and over 65 publications describing
the use of exchange tetramers have appeared to date. Al-
though the majority of conditional MHC ligands reported to
date are based on UV cleavage of a 3-amino-3-(2-nitrophenyl)-
propionic acid residue, one can envisage that for certain appli-
cations UV irradiation would be less practical. Uniform parallel
irradiation, as required for high-throughput screening of large
collections of potential antigens, for example, is often difficult
to achieve, which in turn yields skewed assay results. In addi-
tion, evaporation accelerated by the heat generated by the UV
lamp is problematic when working with minute volumes in, for
example, pMHC microarrays,[19] or in other situations in which
reagents are a limiting factor. In early attempts we tried to ad-
dress these issues by the devel-
opment of an orthogonal che-
mocleavable MHC exchange
ligand, based on the reactivity of
vicinal diols towards sodium
periodate.[3b] Sodium periodate
concentrations of at least
300 mm were required to effectu-
ate peptide exchange, however,
and these conditions appeared
incompatible with exchange
peptides containing oxidation-
prone residues such as Met or
Cys. Recovery of the impaired
T cell staining by utilization of
nonoxidizable Met and Cys
carba-isosteres was only partially
successful, because the tolerance
of these bioisosteres by the rele-
vant T-cell receptor appeared to
be donor-dependent, thus limit-
ing the general applicability of
this methodology.
The vicinal amino alcohol
building block that we present
here conveniently solved these
problems because the peptide—
p*AA—incorporating this moiety and loaded into the MHC
complex was cleaved at a very low NaIO4 concentration
(10 mm), which precludes Met co-oxidation. T cell staining diffi-
culties with Cys-containing exchange peptides were simply
overcome by temporarily caging the Cys residue as a disulfide
during the very mild oxidative exchange reaction. Subsequent
uncaging by a mild reductant (DTT or TCEP) released the
native MHC-bound epitope, eventually resulting in T-cell-reac-
tive exchange tetramers. Notably, Cys disulfide caging has
been made possible by the extremely mild oxidative condi-
tions that enabled cleavage of the 1,2-amino alcohol. A disul-
fide-caged Cys residue can easily be incorporated in the ex-
change peptide during SPPS by making use of the correspond-
ing protected building block. Although N-terminal Ser and Thr
residues remain prone to periodate cleavage,[2b] these residues
can be replaced by other periodate-resistant ones, because the
N-terminal residue of an MHC class I epitope is not critical to
interactions with the T-cell receptor.
Conclusions
In conclusion, the development of a vicinal amino alcohol
building block has made periodate-mediated peptide back-
bone cleavage possible under extremely mild conditions and
without accompanying methionine and disulfide oxidation. As
a representative application we have shown that this cleavable
moiety has truly opened chemically triggered MHC exchange
technology to the broader scientific community, taking away
the need for special laboratory equipment and allowing MHC
class I epitope screening and assessment of T cell reactivities
Figure 2. Staining of PBMCs of healthy donors with HLA-A2.1 exchange tetramers obtained by use either of
10 mm NaIO4 or of UV-mediated exchange as indicated. A) MHC peptide exchange with flu (influenza A matrix-
1(58–66) epitope GILGFVFTL, top panels) or CMV (CMV pp65(495–503) epitope NLVPMVATV, bottom panels). p*UV:
KILGFVFJV, in which J is a photocleavable 3-amino-3-(2-nitrophenyl)propionic acid residue.[22] B) MHC exchange
with CMV before (top panel) and after (bottom panel) treatment with a large excess of NaIO4. Numbers indicate
percentages of MHC tetramer+ cells amongst CD8+ cells.
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without limitations. Furthermore, we can also envisage the ap-
plication of the vicinal amino alcohol building block in other
conditional settings, such as when triggered depletion of effec-
tor peptides or ring-opening of cyclic peptides is desired.
Moreover, incorporation of this building block into a protein
by native chemical ligation, leading to a protein that can be
cleaved at will by application of a mild chemical stimulus, is an
interesting possibility.
Experimental Section
General : All commercial materials
(Aldrich, Fluka, Novabiochem)
were used without further purifica-
tion. Peptide synthesis reagents
(standard amino acid building
blocks and PyBop) were purchased
from Novabiochem. All solvents
were reagent grade or HPLC
grade. Unless stated otherwise, re-
actions were performed under
inert atmospheres. NMR spectra
(1H and 13C) were recorded with
a Bruker Avance 300 spectrometer,
referenced to TMS or residual sol-
vent. LC-MS analysis was per-
formed with a system containing
a Waters 2795 separation module
(Alliance HT), Waters 2996 Photo-
diode Array Detector (190–
750 nm), Waters Alltima C18 (2.1
100 mm) or Phenomenex Kinetex
XB-C18 (2.150 mm) reversed-
phase column and a Micromass
LCT-TOF mass spectrometer. Sam-
ples were run at 0.40 mLmin1
(Waters C18) or 0.80 mLmin1 (Ki-
netex C18) with use of a gradient
of two mobile phases: A) aq.
formic acid (0.1%), and B) formic
acid in CH3CN (0.1%). Data proc-
essing was performed with the aid
of Waters MassLynx 4.1 software.
Preparative HPLC was performed
with a Shimadzu LC-20AD/T instru-
ment fitted with a C18 Vydac
column (Grace Davison Discovery
Sciences) with use of gradient elu-
tion [mobile phases: A) aq. TFA
(0.05%) and B) TFA in CH3CN
(0.05%)]. Gel-filtration chromatog-
raphy was performed with a
Biosep SEC S3000 column (Phe-
nomenex) in PBS (pH 7.4).
Cloning and expression of l-
threonine aldolase : l-Threonine
aldolase DNA from P. putida (acces-
sion number AB001577.1) was
codon-optimised for expression in
E. coli and commercially obtained
from GeneArt. The 1041-base-pair
DNA fragment was then amplified by PCR with use of primers 5’-
GGTGGT CATATG ATGACC GATCAG AGCC and 5’-GGTGGT GGATCC
CTAGTG ATGGTG ATGGTG ATGCGC GCTCAT CACC. The PCR prod-
uct was inserted between the NdeI and BamHI restriction sites of
the commercially available pet3a vector, which yielded plasmid
pRHH1 (5699 bp). E. coli BL21 (DE3) pLysS cells were transformed
with pRHH1 and expression was carried out at 37 8C in Luria–Berta-
ni (LB) medium supplemented with chloramphenicol (34 mgmL1)
and carbenicillin (50 mgmL1). Cells were grown to an OD600nm
value of 0.6 and protein expression was induced by addition of iso-
propyl b-d-thiogalactopyranoside to a final concentration of 1 mm.
Figure 3. A) Concept of cysteine caging and liberation of the native antigenic epitope in the MHC peptide binding
groove under mild conditions. R=SPa. B) Staining of PBMCs of healthy donors with HLA-A2.1 exchange tetramers
obtained by use either of 10 mm NaIO4 or of UV-mediated exchange as indicated. EBV-SPa: EBV BMLF I(259–267) epi-
tope GLC(SPa)TLVAML, in which cysteine is caged with a thiopropanoic acid group. Numbers indicate the percen-
tages of MHC tetramer+ cells of CD8+ cells before (left) and after addition either (middle) of 0.5 mm DTT or (right)
of 0.5 mm TCEP. C) Stimulation of clonal CD8+ T cells specific to the EBV BMLF I(259–267) epitope in complexation
with HLA-A2.1 by direct interaction with the indicated exchanged MHC complexes immobilised on a streptavidin-
coated plate. Similar levels of interferon-g (IFN-g) production, indicating T cell activation, were observed with the
use of EBV-loaded tetramers obtained by UV exchange (middle panel) or with the use of chemo-exchange with
EBV-Spa followed by TCEP-mediated Cys uncaging. HBV: HLA-A2.1 restricted hepatitis B virus core(18–27) epitope,
used here as a control for basal IFN-g levels of nonactivated T cells (left panel).
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After 4 h, the cells were harvested by centrifugation at 4 8C at
4000g for 15 min and taken up in PBS buffer. Cells were then soni-
cated and the lysate was spun at 4 8C at 4000g for 15 min to
remove cell debris. The supernatant containing LTA (39 kDa) was
directly used for the synthetic steps described below.
(2S)-2-Amino-4-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-
hydroxybutanoic acid (2a): A solution of 1a[12] (280 mg, 1 mmol)
in DMSO (2 mL) and a solution of glycine (200 mg, 2.7 mmol) in
KH2PO4 buffer (pH 8.0, 50 mm, 2.6 mL) were added at 0 8C to
KH2PO4 buffer (pH 8.0, 50 mm, 10 mL). LTA lysate (1 mL of 10 mg
proteinmL1) and pyridoxal-5’-phosphate (5 mm in H2O, 75 mL)
were added, and the mixture was placed on a horizontal shaker.
After the mixture had been shaken at room temperature for 16 h,
the reaction was quenched by addition of methanol/AcOH (95:5),
lowering the pH to 3. Et2O was then added to the mixture, and
after the mixture had been stirred for 5 min, the ether layer was
removed. The remaining mixture was filtered over a Strata SCX
cation-exchange solid-phase extraction column (Phenomenex) with
elution with methanol/acetonitrile (1:1) and lyophilized to afford
2a in 10% yield. N.B. The product gradually decomposes in organ-
ic solvents and should be stored dry at 20 8C or immediately
used for the next step. 1H NMR (300 MHz, DMSO): d=7.90 (d, J=
7.9 Hz, 2H), 7.72–7.68 (m, 2H), 7.45–7.31 (m, 4H), 4.36–3.90 (m,
5H), 3.20–3.17 ppm (m, 2H); 13C NMR (300 MHz, DMSO): d=168.64,
156.35, 143.35, 140.65, 127.59, 127.05, 125.15, 120.07 68.24, 65.56,
46.64, 30.65 ppm; HRMS (ESI): calcd: 357.3725 [M+H]+ ; found:
357.1323.
(2S)-4-{[(Allyloxy)carbonyl]amino}-2-amino-3-hydroxybutanoic
acid (2b): Glycine (300 mg, 4 mmol) was added to a solution of 1b
(150 mg, 1 mmol) in KH2PO4 buffer (pH 8.0, 50 mm, 1 mL), followed
by the addition of LTA (1 mL) and pyridoxal-5’-phosphate (5 mm in
H2O, 75 mL). The resulting mixture was placed on a horizontal
shaker for 3 h. The reaction was quenched by addition of metha-
nol/AcOH (95:5), lowering the pH to 3. The mixture was lyophilised
and then purified by flash chromatography (eluents: n-butanol/
H2O/AcOH 2:1:0.5) to afford 2b in 50% yield.
1H NMR (300 MHz,
D2O): d=5.97–5.84 (m, 1H), 5.30–5.81 (m, 2H), 4.53–4.52 (m, 2H),
4.12–4.06 (m, 1H), 3.76 (d, J=3.5 Hz, 0.45H), 3.60 (d, J=4.3 Hz,
0.48H), 3.33–3.18 ppm (m, 2H); 13C NMR (300 MHz, D2O): d=
172.99, 171.88, 132.66, 117.45, 68.76, 66.06, 57.27, 56.89 (minor dia-
stereoisomer), 43.34, 42.68 ppm (minor diastereoisomer).
(2S)-2-[(tert-Butoxycarbonyl)amino]-4-({[(9H-fluoren-9-yl)methox-
y]carbonyl}amino)-3-hydroxybutanoic acid (3a): Compound 2a
(67 mg, 0.19 mmol) was dissolved in water/dioxane/methanol
(20:1:1, v/v/v) and cooled to 0 8C, and solid NaHCO3 (62 mg,
0.76 mmol) was added to the suspension. A solution of di-tert-
butyl dicarbonate (45 mg, 0.21 mmol) in dioxane was added drop-
wise, and the mixture was stirred at 4 8C for one hour. (N.B. The pH
should be kept between 8 and 9, to avoid the retroaldol reaction,
which takes place at pH>9.) The reaction was quenched by lower-
ing the pH to 3 by addition of KHSO4 (1m). The solution was partly
concentrated by cold evaporation, and the water phase was ex-
tracted twice with cold ethyl acetate. The combined organic layers
were washed with brine, dried with Na2SO4 and concentrated to
dryness in vacuo to afford the crude product, which was purified
by flash chromatography (CH2Cl2/methanol 9:1) to afford 3a as
a white glassy solid (47 mg, 53%). 1H NMR (300 MHz, CD3OD): d=
7.69 (d, J=7.7 Hz, 2H), 7.55 (d, J=7.5 Hz, 2H), 7.29–7.18 (m, 4H),
4.25–4.11 (m, 5H), 3.20–3.19 (m, 2H), 1.37 and 1.35 ppm (2s, 9H,
minor and major diastereoisomer, respectively) ; 13C NMR (300 MHz,
CD3OD): d=158.95, 158.44, 145.36, 146.60, 128.77, 128.16, 126.10,
120.91, 80.99, 80.96 (minor diastereoisomer), 72.11 (minor diaste-
reoisomer), 71.29, 67.99, 58.06 (minor diastereoisomer), 57.09,
44.83, 28.68 ppm; MS (ESI): calcd: 478.17 [M+Na]+ ; found: 478.94.
(2S)-4-{[(Allyloxy)carbonyl]amino}-2-[(tert-butoxycarbonyl)ami-
no]-3-hydroxybutanoic acid (3b): The procedure described for 3a
was also used to prepare 3b in 40% yield. 1H NMR (300 MHz,
MeOD): d=6.01–5.88 (m, 1H), 5.35–5.18 (m, 2H), 4.53–4.52 (m,
2H), 4.26–3.95 (m, 2H), 3.33–3.18 (m, 2H), 1.47 ppm (s, 9H);
13C NMR (300 MHz, MeOD): d=174.27, 173.73, 158.80, 158.38,
134.42, 117.56, 80.96, 80.82 (minor), 66.57 (minor), 66.53, 61.93,
58.09 (minor), 57.34, 44.80, 44.64 (minor), 28.69 ppm.
(2R,3R)-4-({[(9H-Fluoren-9-yl)methoxy]carbonyl}amino)-2,3-dihy-
droxybutanoic acid (5): TFA (1.3 mL) was added to a solution of
4[3b] (1 g, 2.5 mmol) in THF/H2O (2.5:1 mL) and the mixture was
stirred for 4 h at room temperature. The solvent was evaporated in
vacuo to afford 5 (870 mg) as a white powder that was used as
such for the next step. 1H NMR (300 MHz, DMSO): d=7. 89 (d, J=
7.6 Hz, 2H), 7.77 (d, J=7.6 Hz, 2H), 7.44–7.30 (m, 4H), 7.15 (br, 1H),
4.28–4.18 (m, 3H), 3.91 (d, J=3.9 Hz, 1H) 3.76–3.70 (m, 1H), 3.25–
3.01 ppm (m, 2H); 13C NMR (300 MHz, DMSO): d=173.73, 157.29,
143.89, 140.66, 127.57, 127.04, 125.24, 120.05, 72.90, 71.32, 65.44,
46.67, 43.11 ppm.
Methyl (2R,3R)-4-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-
2,3-dihydroxybutanoate (6): Concentrated HCl (1 mL) was added
to a solution of 5 (870 mg, 2.4 mmol) in methanol (100 mL) and
the mixture was stirred at 65 8C for 6 h. The solvent was evaporat-
ed, and the crude product was purified by flash chromatography
(ethyl acetate/hexanes 3:2!2:1) to afford 6 as a white solid
(690 mg, 77%). 1H NMR (300 MHz, CDCl3): d=7.77 (d, J=7.6 Hz,
2H), 7.59 (d, J=7.6 Hz, 2H), 7.44–7.30, 5.20 (br, 1H), 4.47 (d, J=
6.5 Hz, 2H), 4.24–4.23 (dd, J=6.5 Hz, 1H), 4.14 (d, J=5.86 Hz, 1H),
3.99–3.93 (m, 1H) 3.84 (s, 3H), 3.53–3.38 ppm (m, 2H); 13C NMR
(300 MHz, CDCl3): d=173.31, 157.67, 143.79, 141.36, 127.76, 127.09,
124.95, 120.03, 72.16, 71.76, 67.01, 52.85, 47.23, 42.67 ppm.
Methyl (4R,5R)-5-[({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-
methyl]-2-oxy-1,3,2-dioxathiolane-4-carboxylate (7): Et3N (1.1 mL,
8.14 mmol) and a solution of SOCl2 (0.3 mL, 4.1 mmol) in dry
CH2Cl2 (2 mL) were added at 0 8C to a solution of 6 (690 mg,
1.85 mmol) in dry CH2Cl2 (11 mL). The resulting mixture was stirred
at 0 8C until disappearance of the starting material was observed
by TLC (about 1.5 h). The mixture was then poured into cold water
and extracted with ethyl acetate. The organic layer was washed
with water and brine and dried over Na2SO4. Concentration to dry-
ness in vacuo yielded the crude product, which was purified by
flash chromatography (ethyl acetate/Hex 1:1) to afford 7 as
a yellow oil (630 mg, 80%). 1H NMR (300 MHz, CDCl3): d=7.79 (d,
J=7.6 Hz, 2H), 7.62 (d, J=7.6 Hz, 2H), 7.58–7.33 (m, 4H), 5.32–5.20
(m, 3H), 4.49 (br s, 2H), 3.78 (s, 3H), 3.74–3.65 (m, 1H), 3.44–
3.34 ppm (m, 1H).
Methyl (4R,5R)-5-[({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-
methyl]-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide (8): H2O
(6 mL), RuCl3·xH2O (4.5 mg, 0.02 mmol) and NaIO4 (643 mg,
3 mmol) were added at 0 8C to a solution of 7 (630 mg, 1.5 mmol)
in CCl4/CH3CN 10 mL (1:1, v/v). After the slurry had been stirred for
1 h at 0 8C, Et2O (30 mL) and hexanes (30 mL) were added. The or-
ganic layer was separated, filtered over filter paper and washed
with aq. NaHCO3 (1%). The water phase was back-extracted with
Et2O, and the combined organic layers were washed with brine,
dried with Na2SO4 and concentrated to dryness in vacuo to afford
8 as a white powder (470 mg, 70%). 1H NMR (300 MHz, CDCl3): d=
7.70 (d, J=7.6 Hz, 2H), 7.50 (d, J=7.6 Hz, 2H), 7.37–7.23 (m, 4H),
5.25–5.06 (m, 2H), 4.42 (br s, 2H), 4.17–4.12 (dd, 1H), 3.78 (s, 3H),
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3.62–3.49 ppm (m, 2H); 13C NMR (300 MHz, CD3OD): d=164.12,
156.15, 143.59, 141.46, 127.89, 127.21, 124.96, 120.06, 80.74, 77.54,
67.34, 53.73, 47.08, 40.34 ppm; FTIR (solid): n˜=1716, 1396,
1211 cm1.
Methyl (2S,3R)-2-azido-4-({[(9H-fluoren-9-yl)methoxy]carbonyl}a-
mino)-3-hydroxybutanoate (9): NaN3 (130 mg, 2 mmol) was added
at 0 8C to a solution of 8 (420 mg, 1 mmol) in acetone (4 mL) and
water (0.5 mL), and the mixture was stirred at room temperature
for 2 h. Cold H2SO4 (20%) and Et2O (1:1, v/v, 10 mL) were added
and stirring was continued for 16 h. Et2O was added, and the
phases were separated. The water phase was washed with CH2Cl2.
The organic phases were washed with water and brine. The organ-
ic layers were combined and evaporated in vacuo to afford 9
(280 mg, 64%). 1H NMR (300 MHz, CDCl3): d=7.75 (d, J=7.5 Hz,
2H), 7.57 (d, J=7.4 Hz, 2H), 7.42–7.29 (m, 4H), 4.47 (d, J=6.5 Hz,
2H), 4.23–4.19 (m, 2H), 3.87–3.84 (m, 1H), 3.37–3.28 ppm (m, 2H);
13C NMR (300 MHz, CD3OD): d=169.22, 157.79, 143.55, 141.34,
127.81, 127.16, 124.95, 120.01, 71.04, 67.65, 63.74, 53.27, 47.07,
44.24 ppm; FTIR (solid): n˜=2112, 1750, 1701, 1527, 1267 cm1.
(2S,3R)-2-Amino-4-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-
3-hydroxybutanoic acid (10): Trimethyltin (500 mg, 2.5 mmol) was
added to a solution of 9 (200 mg, 0.5 mmol) in dichloroethane
(6 mL) and the solution was stirred at 82 8C for 3 h. The mixture
was allowed to cool to room temperature, and cold ethyl acetate
(5 mL) was added, followed by cold aq. HCl (5%, 5 mL). The mix-
ture was stirred for 10 min, extra ethyl acetate was added, and the
phases were separated. The organic layer was washed with water
and brine, dried with Na2SO4 and concentrated to dryness in
vacuo. The crude product was purified over a short silica column
(CH2Cl2/methanol 98:2!95:5) to afford the pure product 10 as an
off-white solid (130 mg, 68%). 1H NMR (300 MHz, CD3OD): d=7.85
(d, J=7.8 Hz, 2H), 7.73 (d, J=7.8 Hz, 2H), 7.42–7.29 (m, 4H), 4.40
(d, J=7.0 Hz, 2H), 4.24–4.20 (m, 2H), 3.90–3.82 (m, 1H), 3.28–
3.23 ppm (m, 2H); 13C NMR (300 MHz, CD3OD): d=173.32, 159.78,
146.04, 143.37, 129.55, 128.94, 126.92, 121.72, 72.88, 68.50, 65.55,
49.24, 45.71 ppm; FTIR (solid): n˜=3300, 2112, 1741, 1672,
1541 cm1; MS (ESI): calcd: 382.1277 [M+H]+ ; found: 383.1122.
Peptide synthesis : All peptides were synthesised by standard
Fmoc SPPS on a 25 mmol scale with a Syro II MultiSyntech automat-
ed peptide synthesiser. Removal of Alloc groups was achieved with
Pd(PPh3)4 (3 equiv) in CH2Cl2/AcOH/N-methylmorpholine (37:2:1)
mixtures. Azido groups were reduced by treatment with Bu3P
(5 equiv) in THF containing a few droplets of water. Peptides were
cleaved from the resin and deprotected with TFA/iPr3SiH/H2O
(95:2.5:2.5), precipitated in cold n-pentane/diethyl ether and puri-
fied by RP-HPLC (C18). All peptides were analysed by LC-MS and
used at >98% purity.
Protein expression and purification : MHC class I refolding reac-
tions were performed as described, and class I complexes were
purified by gel-filtration chromatography. Biotinylation and MHC
tetramer formation were performed as described.[20]
Protocol for hypersensitive MHC peptide exchange triggered by
NaIO4 : Exchange peptide (pH 7.4, 50 mm) and biotinylated HLA-
A2.1::p*AA (0.5 mm) in PBS (50 mL) were treated with NaIO4 (10 mm)
for 45 min at room temperature. Optionally, subsequent uncaging
of disulfide-protected Cys residues is achieved by treatment with
DTT or TCEP (500 mm) for 15 min. Exchanged monomers were used
for tetramerisation as previously described[20] or for cytokine re-
lease assays as described below.
T cells : For analysis of MHC tetramer binding and T cell responses
in human samples, peripheral blood mononuclear cells of healthy
volunteers were obtained by Ficoll gradient separation. A cryopre-
served CD8+ T-cell clone, derived from a healthy donor expressing
the HLA-A2.1 complex specifically binding EBV BMLF I(259–267), was
kindly provided by Ms. Marit van Buuren (NKI, Amsterdam, NL).
Cryopreserved cells were thawed 24 h prior to cytokine release
assays and were suspended in cytotoxic T lymphocyte (CTL)
medium [RPMI 1640 medium supplemented with Glutamax,
HEPES, human serum (10%) and penicillin/streptomycin
(6000 UmL1)] .
Tetramer staining : Cells were stained with the indicated MHC tet-
ramers for 4 min at 37 8C. Subsequently, cells were incubated with
anti-CD8 antibody (BD Biosciences) for 10–15 min at 25 8C. Data ac-
quisition and analysis was carried out with a FACSCalibur (Becton
Dickinson) instrument and use of FlowJo software.
Cytokine release assay : T cell activity was analysed by an adapted
procedure based on the use of immobilised MHC tetramers.[21]
Briefly, exchange monomers (100 mL per well) were added to a 96-
well streptavidin coated plate (NUNC, Immobilizer Streptavidin,
#436014) blocked with bovine serum albumin (BSA)/PBS (2%).
After 30 min incubation, the plate was washed with PBS. T cells
were spun at 1700 rpm for 10 min and were resuspended in CTL
medium supplemented with protein transport inhibitor (1 mLmL1,
GolgiPlug, BD Biosciences #555029) at 4105 cellsmL1. T cells
were added (100 mL per well) to the MHC-streptavidin coated
plate, and the plate was briefly centrifuged (700 rpm, 3 min) to en-
hance MHC/Tcell contact before incubation for 4 h at 37 8C under
CO2 (7%). The cells were pelleted at 1700 rpm for 3 min, resus-
pended in FACS buffer [50 mL, BSA (0.5%), NaN3 (0.02%) in PBS]
and transferred to a 96-well U-bottom plate (BD FALCON #353077).
Cells were stained with FITC-conjugated antibodies to CD8 (BD Bio-
sciences, #345772) for 15 min at 25 8C, fixed and permeabilised (BD
Cytofix/Cytoperm kit, #554714), and stained with APC-conjugated
antibodies to IFNg (BD Biosciences, #341117) for 30 min at 4 8C.
Samples were analysed by flow cytometry.
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